TY - JOUR
T1 - Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis
AU - McCracken, G. H.
AU - Sande, M. A.
AU - Lentnek, A.
AU - Whitley, R. J.
AU - Scheld, W. M.
N1 - Funding Information:
Financial support: This work was supported by a contract to the Infectious Diseases Society ofAmerica from the U.S. Food and Drug Administration (no. HHS 223-88-130 I).
PY - 1992/11
Y1 - 1992/11
N2 - Predisposing conditions for acute bacterial meningitis include prematurity, young age, management in an intensive care setting, low socioeconomic background, and crowded living conditions. Clinical findings vary with age and may be nonspecific (altered feeding behavior) or specific (Kernig and Brudzinski signs). Examination and culture of cerebrospinal fluid (CSF) are essential for diagnosis. Antigen identification in CSF, serum, or urine by latex agglutination or other techniques can be useful in the identification of the pathogen. Randomized, controlled studies with a single-, double-, or evaluator-blinded design are encouraged. Among neonates, infants, and children, CSF should be examined again 24-36 hours after initiation of therapy. Outcomes should be judged by both clinical and microbiological criteria. Assessment of microbiological outcome is paramount.
AB - Predisposing conditions for acute bacterial meningitis include prematurity, young age, management in an intensive care setting, low socioeconomic background, and crowded living conditions. Clinical findings vary with age and may be nonspecific (altered feeding behavior) or specific (Kernig and Brudzinski signs). Examination and culture of cerebrospinal fluid (CSF) are essential for diagnosis. Antigen identification in CSF, serum, or urine by latex agglutination or other techniques can be useful in the identification of the pathogen. Randomized, controlled studies with a single-, double-, or evaluator-blinded design are encouraged. Among neonates, infants, and children, CSF should be examined again 24-36 hours after initiation of therapy. Outcomes should be judged by both clinical and microbiological criteria. Assessment of microbiological outcome is paramount.
UR - http://www.scopus.com/inward/record.url?scp=0026480260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026480260&partnerID=8YFLogxK
U2 - 10.1093/clind/15.Supplement_1.S182
DO - 10.1093/clind/15.Supplement_1.S182
M3 - Article
C2 - 1477228
AN - SCOPUS:0026480260
SN - 1058-4838
VL - 15
SP - S182-S188
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -